1 in 5 cancer drug denials overturned: UAE clinics face an appeals paperwork test

One in 5 appealed cancer drug denials was overturned in a JAMA Network Open study published on 23 July 2026, a finding UAE oncology clinics should read as a warning about prior-authorisation files, denial codes and escalation discipline.

The study, reported by CURE on 21 August 2026, is based on the US Medicare Part D system. The operating lesson travels well to Dubai, Abu Dhabi and the northern emirates. Cancer medicines are expensive, often time-sensitive and frequently tied to biomarker evidence. A missing pathology report can become a cash-flow issue for the provider, a treatment delay for the patient and a liability question for the prescribing oncologist.

What the study found

Youngmin Kwon, PhD, a postdoctoral research fellow in health policy at Vanderbilt University Medical Center, led a cross-sectional review of 4,952 second-level appeals for denied anticancer medicines from 2020 to 2024. The study found 19.5% of appeals received favourable reviews. Targeted therapies made up 2,889 cases, or 58.3% of the sample.

"A simple mishap, such as forgetting to attach a lab result or a supporting citation, could mean weeks of delay."
Youngmin Kwon, PhD, Vanderbilt University Medical Center

The highest success rate came where drugs appeared to be prescribed on-label but failed preapproval coverage criteria. Reviewers approved 61.1% of those appeals. By contrast, off-label or non-medically accepted indication denials were the largest group, at 3,410 appeals, and had a 16.5% favourable review rate. In successful off-label appeals, 87.9% had support from a recognised compendium or peer-reviewed literature.

Why this matters in Dubai

For Dubai operators, the immediate reader is the COO. Dubai Health Authority (DHA) regulates Dubai healthcare and runs a unified insurance complaint channel for insured members through the DHA insurance complaint service. Before a patient reaches that point, the provider needs the insurer's written rejection reason, the policy clause, the diagnosis code, the regimen, the biomarker report and the treating oncologist's justification in one file.

The CFO should treat each denial as a receivable with a clinical clock attached. UAE public medicine price lists show why the amounts are material. A 2017 Dubai resolution listed trastuzumab 440mg injection at AED 14,062.50 in DHA pharmacies. Current oncology drug prices should be checked through the Emirates Drug Establishment or the applicable payer formulary because list prices, procurement terms and network rules change by product and plan.

• Clinic action: keep a denial log by insurer, drug, indication, biomarker status and outcome.
• Patient action: ask for the rejection letter, medical reason, policy basis and appeal deadline in writing.
• Insurer action: separate missing-document denials from clinical ineligibility denials.
• Medical director action: prebuild evidence templates for on-label use, off-label use and compassionate-access requests.

Abu Dhabi and the northern emirates

In Abu Dhabi and Al Ain, the relevant regulator is the Department of Health Abu Dhabi (DOH). DOH's insurance complaint service states that most complaints are resolved within 30-60 working days, with fraud and abuse cases taking longer. The service covers Thiqa, Basic, Enhanced and Aounak programmes, and lists required documents including the application form, supporting documents, clarification letter, Emirates ID, residency visa and valid health insurance card.

For the northern emirates, the relevant federal regulator is the Ministry of Health and Prevention (MOHAP), while pharmaceutical product registration and price-list services have been moving to the Emirates Drug Establishment. Patients and clinics should verify whether the medicine is registered, whether the indication matches the label, and whether the insurer requires prior approval before the first cycle. For many private plans, including policies administered or sold by large UAE insurers such as Daman and Sukoon, the decisive document is still the policy schedule and payer portal response.

The practical lesson is narrow. Appeals work when the clinical case is clear and the file proves it. UAE oncology providers should audit denied anticancer medicines monthly, compare reversal rates by insurer and escalate repeated documentary disputes through DHA, DOH or MOHAP channels as applicable. Patients looking for a licensed oncology provider can start with the UAE Open Healthcare Directory and then confirm insurance acceptance with the clinic before booking.